NASDAQ : TLX
Telix Pharmaceuticals Limited — Key statistics
Healthcare · Biotechnology · Australia
Last price 9.51 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.22B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.13B |
| Enterprise Value | 3.47B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 22, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 339.78M |
| Shares Change (YoY) | +2.75% |
| Shares Change (QoQ) | +5.42% |
| Owned by Insiders (%) | 14.86% |
| Owned by Institutions (%) | 44.26% |
| Float | 273.54M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 94.41 |
| Forward PE | 507.45 |
| PS Ratio | 3.51 |
| Forward PS | 3.22 |
| PB Ratio | 6.41 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 103.30 |
| EV / Sales | 3.88 |
| EV / EBITDA | 49.57 |
| EV / EBIT | 62.62 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.01 |
| Quick Ratio | 1.74 |
| Debt / Equity | 1.19 |
| Debt / EBITDA | 7.47 |
| Debt / FCF | n/a |
| Interest Coverage | 3.69 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 7.37% |
| Return on Assets (ROA) | 2.71% |
| Return on Invested Capital (ROIC) | 6.78% |
| Return on Capital Employed (ROCE) | 4.94% |
| Weighted Average Cost of Capital (WACC) | 6.50% |
| Revenue Per Employee | $752,352 |
| Profits Per Employee | $28,291 |
| Employee Count | 1,184 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 12.58 |
Taxes
| Measure | Value |
|---|
| Income Tax | -4.68M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -14.35% |
| 50-Day Moving Average | 11.01 |
| 200-Day Moving Average | 9.91 |
| Relative Strength Index (RSI) | 35.68 |
| Average Volume (20 Days) | 357,122 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 352,936 |
| Short Previous Month | 426,829 |
| Short % of Shares Out | 0.11% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.76 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 890.79M |
| Gross Profit | 423.71M |
| Operating Income | 55.26M |
| Pretax Income | 28.82M |
| Net Income | 33.50M |
| EBITDA | 69.81M |
| EBIT | 55.26M |
| Earnings Per Share (EPS) | $0.10 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 251.91M |
| Total Debt | 579.86M |
| Net Cash | -327.95M |
| Net Cash Per Share | -$0.97 |
| Equity (Book Value) | 487.68M |
| Book Value Per Share | 1.44 |
| Working Capital | 245.68M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.01M |
| Capital Expenditures | -33.48M |
| Depreciation & Amortization | 14.55M |
| Net Borrowing | 115.13M |
| Free Cash Flow | -45.49M |
| FCF Per Share | -$0.13 |
Margins
| Measure | Value |
|---|
| Gross Margin | 47.57% |
| Operating Margin | 6.20% |
| Pretax Margin | 3.24% |
| Profit Margin | 3.76% |
| EBITDA Margin | 7.84% |
| EBIT Margin | 6.20% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.75% |
| Shareholder Yield | -2.75% |
| Earnings Yield | 1.06% |
| FCF Yield | -1.45% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $20.54 |
| Price Target Difference | 125.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 15.56% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.19 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |